|
SPORE in Pancreatic Cancer
|
3P20CA101936-05S1
|
$521,256
|
ABBRUZZESE, JAMES
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
4R44CA124032-02
|
$1,473,388
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Clinical study of AdV-tk radiogene therapy for malignant glioma
|
5R44CA107745-05
|
$510,001
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Initiation of DNA Replication in Mammalian Cells
|
ZIA BC 010411
|
$712,550
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Immuno/Immunogene Therapies for Thoracic Malignancies
|
5P01CA066726-13
|
$1,203,367
|
Albelda, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Stem Cells as Delivery Vehicles and Imaging Probes for Glioma Gene Therapy
|
5R21CA129801-02
|
$195,750
|
ALI, SYED
|
HENRY FORD HEALTH SYSTEM
|
|
THE THERAPY OF AML
|
5P01CA055164-17
|
$2,440,745
|
ANDREEFF, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Extension of Radiotherapy Research
|
3P01CA006294-44S1
|
$300,000
|
ANG, K
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
5T32CA009515-25
|
$638,492
|
APPELBAUM, FREDERICK
|
UNIVERSITY OF WASHINGTON
|
|
EGFR antisense DNA added to cetuximab and radiotherapy for head and neck cancer
|
5R21CA130241-02
|
$344,985
|
ARGIRIS, ATHANASSIOS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
DF/HCC Kidney Cancer SPORE
|
2P50CA101942-06A1
|
$2,300,000
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Molecular Control of EGF Receptor Down-Regulation
|
5R01CA099163-09
|
$329,014
|
Band, Hamid
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Zinc Finger Recombinases for Endogenous Genome Tailoring
|
5R21CA126664-02
|
$251,641
|
BARBAS, CARLOS
|
SCRIPPS RESEARCH INSTITUTE
|
|
Malignant melanoma: Regulation by AP-2 and PAR-1
|
5R01CA076098-10
|
$271,063
|
BARELI, MENASHE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Development of Targeted Therapy for ERK Pathway in Breast Cancer
|
1K99CA139006-01A1
|
$114,575
|
Bartholomeusz, Chandra
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Postdoctoral Research Training in Biotherapy of Cancer
|
5T32CA113263-04
|
$4,336
|
BARTLETT, DAVID
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Imaging of gene expression in glioblastoma
|
5R01CA109620-04
|
$277,775
|
Basilion, James
|
CASE WESTERN RESERVE UNIVERSITY
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
3P50CA083639-09S1
|
$57,442
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
3P50CA083639-10S1
|
$141,526
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Paul Calabresi Clinical Oncology Award
|
5K12CA088084-10
|
$375,141
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of Texas MD Anderson SPORE in Ovarian Cancer
|
5P50CA083639-10
|
$2,001,032
|
BAST, ROBERT
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor-Targeting Oligonucleotides
|
5R01CA122383-04
|
$255,082
|
BATES, PAULA
|
UNIVERSITY OF LOUISVILLE
|
|
Characteristics of Multidrug Resistance in Human Tumors
|
5R01CA040570-22
|
$261,339
|
BECK, WILLIAM
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
Mechanism of p53 Silencing By Adenovirus E1B 55K Protein
|
5R01CA064799-13
|
$223,112
|
BERK, ARNOLD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Career Development in Pediatric and Medical Oncology
|
2K12CA076930-11
|
$595,080
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Pediaric Oncology Research Training Program
|
5T32CA009351-31
|
$223,195
|
BERNSTEIN, IRWIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Image-guided Prodrug and siRNA Targeting of Cancer
|
1R01CA138515-01A1
|
$340,300
|
Bhujwalla, Zaver
|
JOHNS HOPKINS UNIVERSITY
|
|
Improving Suicide Genes for Cancer Gene Therapy
|
5R01CA085939-10
|
$263,112
|
BLACK, MARGARET
|
WASHINGTON STATE UNIVERSITY
|
|
Re-activation of maspin tumor suppressor gene by designed transcription factors
|
5R01CA125273-03
|
$293,003
|
BLANCAFORT, PILAR
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
|
Research Training Program in Surgical Oncology
|
5T32CA091078-08
|
$348,990
|
Bland, Kirby
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Mechanisms of Viral Fusion and Inactivation
|
ZIA BC 008303
|
$384,413
|
Blumenthal, Robert
|
CCR (NCI)
|
|
Lipid-based Nanocapsules and Triggered Chemotherapy
|
ZIA BC 010652
|
$576,620
|
Blumenthal, Robert
|
CCR (NCI)
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
2R01CA098706-06A1
|
$286,978
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Tumor exosomes as agents of genetic change
|
1R01CA141150-01
|
$293,682
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Regulation of the Sodium/Iodide Symporter in Breast
|
5R01CA089364-07
|
$215,460
|
BRENT, GREGORY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
|
1R01CA138738-01
|
$393,420
|
Brentjens, Renier
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
PDX-1 is a Therapeutic Target for Pancreatic Cancer
|
5R01CA095731-07
|
$274,814
|
BRUNICARDI, FRANCIS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Gene repression by HSF1 during hyperthermia and other stresses.
|
5R01CA077465-06
|
$227,020
|
CALDERWOOD, STUART
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Cell Therapy of Refractory Leukemia
|
5R01CA113482-04
|
$289,553
|
CAMPANA, DARIO
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Image-guided Gene and Virotherapy for Pancreatic Cancer
|
5K08CA103859-05
|
$131,220
|
CARLSON, STEPHANIE
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Understanding and Eliminating Oncogenic EGFR Signaling in Malignant Glioma
|
1U01CA141556-01
|
$677,676
|
CHAREST, ALAIN
|
TUFTS MEDICAL CENTER
|
|
Overcoming Immune Suppression to Enhance Tumor Vaccine Efficacy
|
2R01CA090427-06A2
|
$328,038
|
Chen, Si-Yi
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Combination gene therapy for metastatic colon cancer
|
5R01CA070337-13
|
$287,106
|
CHEN, SHU-HSIA
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
Myeloid suppressor cell-mediated immune suppression of tumor specific T cells
|
5R01CA109322-04
|
$262,923
|
CHEN, SHU-HSIA
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
Ultrasound-guided gene delivery in pancreatic cancer
|
1R03CA140024-01
|
$70,542
|
Claudio, Pier Paolo
|
MARSHALL UNIVERSITY
|
|
Ultrasound guided site-specific gene delivery in prostate cancer
|
1R21CA131395-01A2
|
$184,800
|
Claudio, Pier Paolo
|
MARSHALL UNIVERSITY
|
|
Prevention & Metastasis: Final Frontiers in Colon Cancer
|
3U01CA084239-10S1
|
$224,953
|
COFFEY, ROBERT
|
VANDERBILT UNIVERSITY
|
|
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
|
5R01CA123159-03
|
$278,768
|
COLE, DAVID
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
MOTILITY AND INVASION
|
5P01CA100324-07
|
$2,056,747
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Boosting anti-tumor immune responses by modulating genes with nanoparticles
|
1R21CA132026-01A1
|
$179,782
|
Conejo-Garcia, Jose
|
DARTMOUTH COLLEGE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|